TCM
ALXN

TAM Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

TAM Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-39,110
Closed -$4.36M – 11
2018
Q1 		$4.36M Buy
39,110
+9,378
+32% +$1.12M 4.12% 6
2017
Q4 		$3.3M Buy
+29,732
New +$3.62M 2.94% 10
2016
Q3 		– Sell
-21,408
Closed -$2.46M – 5
2016
Q2 		$2.46M Buy
+21,408
New +$3.04M 100% 1

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TAM Capital Management's ALXN Position: Q2 2018 in Review

TAM Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 39,110 shares — an estimated $4.36M sold.

TAM Capital Management first reported a position in ALXN in Q2 2016 and held it in 3 quarters. The position peaked at $4.36M in Q1 2018. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • TAM Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • TAM Capital Management sold 39,110 Alexion Pharmaceuticals shares in Q2 2018, an estimated $4.36M.
  • TAM Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • TAM Capital Management's Alexion Pharmaceuticals position peaked at $4.36M in Q1 2018.
  • 601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on TAM Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.